Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexbudesonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 13/20 | 1.00 |
| ▸ | PGR | P06401 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | IL5 | P05113 | 1/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 1/20 | 1.00 |
| ▸ | AR | P10275 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | MMP9 | P14780 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Budesonide SCHEMBL16139563 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL17168987 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL9763339 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL12440030 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL19635 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL10020756 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL17151422 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL17971368 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL13918824 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL21570019 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050317-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | US | disclosed |
| EP-3566841-B1 | MANUFACTURING OF SMALL FILM STRIPS | AQUESTIVE THERAPEUTICS INC (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4304554-A1 | DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES | Aquestive Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230414452-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | US | disclosed |
| EP-4277611-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11806311-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230149304-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230145752-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2023076281-A1 | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20230131450-A1 | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| WO-2004030659-A1 | SUSTAINED RELEASE POROUS MICROPARTICLES FOR INHALATION | ACUSPHERE, INC. (US) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004023984-A2 | NOVEL COMPOSITION AND METHOD FOR TREATMENT OF UPPER RESPIRATORY CONDITIONS | SMITH C STEVEN (US) | 2004-03-25 | — | — | WO | disclosed |
| EP-1033991-B1 | MOMETASONE FUROATE SUSPENSIONS FOR NEBULIZATION | SCHERING CORP (US) | 2002-04-17 | — | — | EP | disclosed |
| US-6250300-B1 | System for dispensing pharmaceutically active compounds | AB ASTRA (SE) | 2001-06-26 | — | — | US | disclosed |
| US-6187765-B1 | CONTAINING NONIONIC SURFACTANT, SODIUM OR POTASSIUM CHLORIDE, WATER AND, OPTIONALLY, A PH BUFFER | SCHERING CORPORATION | 2001-02-13 | — | — | US | disclosed |
| EP-1033991-A1 | MOMETASONE FUROATE SUSPENSIONS FOR NEBULIZATION | SCHERING CORPORATION (US) | 2000-09-13 | — | — | EP | disclosed |
| US-5934273-A | System for dispensing pharmaceutically active compounds | AB ASTRA (SE) | 1999-08-10 | — | — | US | disclosed |
| WO-1999018971-A1 | MOMETASONE FUROATE SUSPENSIONS FOR NEBULIZATION | SCHERING CORPORATION (US) | 1999-04-22 | — | — | WO | disclosed |
| US-5642728-A | System for dispensing pharmaceutically active compounds | AB ASTRA (SE) | 1997-07-01 | — | — | US | disclosed |
| US-5049389-A | Non-phospholipd lipid, delivery by inhalation | LIPOSOME TECHNOLOGY, INC. (US) | 1991-09-17 | — | — | US | disclosed |